A marine carotenoid synthesized by microalgae, with antioxidant potency estimated at 550× vitamin E in some assays. The human longevity evidence is early-stage and primarily surrogate-endpoint driven.
Astaxanthin is a xanthophyll carotenoid — the pigment that gives salmon, flamingos, and shrimp their characteristic color. It is synthesized primarily by the microalgae Haematococcus pluvialis.
What distinguishes it structurally from other carotenoids is its polar end groups, which allow it to span the cell membrane bilayer rather than embed only in the lipid core. This is hypothesized to provide better protection against both lipid peroxidation and aqueous phase oxidative damage than beta-carotene or lycopene. Its in vitro antioxidant potency — often cited as 550× vitamin E — reflects this structural feature, though in vitro potency does not predict in vivo clinical efficacy.
The longevity hypothesis centers on oxidative stress as a driver of aging — one of the twelve hallmarks. Astaxanthin's proposed role is to reduce this oxidative burden in tissues where other antioxidants have limited access. The question is whether there is clinical evidence to support this in humans.
Astaxanthin has consistent oxidative stress marker reductions across multiple small RCTs and a good tolerability profile. The evidence tier is Emerging — it has human trial signal, but exclusively on surrogate oxidative stress endpoints with no aging population data and no hard longevity outcomes.
Whether reducing oxidative stress biomarkers in healthy adults translates to longevity benefit is an open question. Antioxidant supplementation trials targeting hard outcomes — most notably SELECT for vitamin E — have been neutral or harmful. Astaxanthin's structural distinctiveness from vitamin E may matter, but this has not been tested in outcome trials.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.